luteolin

Overview

Luteolin is a naturally occurring flavone widely distributed in edible plants and medicinal herbs. It is a dietary polyphenol of interest in biomedical research because of its reported antioxidant and anti-inflammatory properties, as well as broader pharmacological potential. In the recent literature provided, luteolin is also described as a biopharmaceutical classification system (BCS) Class II compound, indicating low aqueous solubility but relatively favorable permeability, a profile that has motivated formulation research to improve its delivery.

Biologically, luteolin has been investigated in relation to oxidative stress, apoptosis, inflammatory signaling, and disease-modifying effects in several experimental settings. Recent studies have explored its activity in cancer, neuroprotection, hearing loss, sepsis-associated encephalopathy, and myocardial infarction repair, often in combination with advanced delivery systems such as nanosuspensions, PEGylated nano-vesicular platforms, nanocomposites, and hydrogels. It has also been quantified as a phytochemical marker in plant materials and herbal preparations, reflecting its importance in natural product analysis and quality control.

Focus of Latest Publications

Recent publications document luteolin's therapeutic potential across multiple organ systems and pathological contexts, with particular emphasis on overcoming its poor aqueous solubility and limited bioavailability through advanced formulation strategies. Studies have explored encapsulation approaches including WPI-Pueraria lobata composite gels, PEGylated aspasomes, lactoferrin-chondroitin sulfate nanoparticles, and nanosuspensions to enhance intestinal absorption, brain penetration, and target-tissue delivery. These delivery platforms consistently demonstrated improved stability, enhanced cellular uptake, and superior bioactivity compared to free luteolin in both in vitro and in vivo models.

In metabolic and systemic inflammation contexts, luteolin-based interventions showed efficacy in adipose tissue dysfunction and insulin resistance. A WPI-encapsulated formulation promoted thermogenic gene expression (UCP1, Pgc-1α, Prdm16, Cidea) in brown adipocytes and restored insulin sensitivity in white adipocytes impaired by inflammatory stimuli, while simultaneously suppressing pro-inflammatory cytokine production (IL-6, TNF-α, IL-1β) in macrophage models. These findings aligned with observations in sepsis-associated encephalopathy, where luteolin-loaded nanocomposites shifted microglia polarization from the pro-inflammatory M1 phenotype toward the anti-inflammatory M2 phenotype via suppression of the TLR4/MyD88/NF-κB pathway.

Luteolin's neuroprotective capacity emerged across stress-related and degenerative contexts. PEGylated luteolin aspasomes administered to chronically stressed rats enhanced spatial memory, attenuated depressive-like behavior, and reduced hippocampal acetylcholinesterase activity while increasing brain-derived neurotrophic factor levels. The flavonoid additionally demonstrated protective effects against noise-induced hearing loss through mitigation of oxidative stress and apoptosis, potentially via regulation of the EGR1/SPRY4 axis.

In cardiac pathology, an injectable hydrogel incorporating luteolin addressed the multifactorial injury cascade following myocardial infarction by simultaneously reducing inflammatory cytokines, alleviating oxidative stress through Nrf2/HO-1 pathway activation, and preserving connexin 43-mediated electrical coupling to reduce arrhythmia incidence. Preliminary evidence also indicated luteolin's potential in oncology, with studies identifying the flavonoid as an inhibitor of cervical cancer cell growth through carbonic anhydrase II suppression. Across diverse formulations and applications, luteolin consistently engaged antioxidant and anti-inflammatory mechanisms involving nuclear factor-kappa B and phosphoinositide 3-kinase signaling.